Dabrafenib (Tefila) targeted drug action mechanism and cancer cell inhibition principle

Dabrafenib (Dabrafenib) is a selective oral targeted drug mainly developed for patients with BRAF V600 mutation-positive tumors. BRAF gene mutations, especially V600E and V600K, can lead to abnormal activation of the MAPK/ERK signaling pathway, thereby driving excessive proliferation and survival of tumor cells. The emergence of dabrafenib provides new treatment options for patients with BRAF mutations such as melanoma and non-small cell lung cancer.

BRAFis a serine/threonine kinase and a key member of the MAPK signaling pathway. When BRAF undergoes mutations such as V600E, its kinase activity is continuously activated, and even in the absence of exogenous growth factor signals, it can continue to drive the phosphorylation of MEK and ERK, promoting the growth of cancer cells. Dabrafenib binds to the ATP binding pocket of mutant BRAF and inhibits its kinase activity, thus blocking the MAPK cascade reaction and ultimately reducing the downstream ERK-mediated oncogene transcriptional activity.

While inhibitingBRAF activity, dabrafenib effectively reduces the abnormal proliferation and metastasis ability of tumor cells and induces cancer cells to enter a state of apoptosis or growth arrest. Unlike traditional chemotherapy, dabrafenib does not rely on cytotoxicity to kill cancer cells, but cuts off the "pathways" that cancer cells rely on to survive by precisely blocking signal transduction. Clinical studies have shown that dabrafenib can significantly improve the objective response rate and delay disease progression in melanoma patients carrying BRAF V600 mutations.

The mechanism of action of dabrafenib highlights the value of precision medicine, which is to specifically inhibit driver gene mutations. However, monotherapy may reduce efficacy due to activation of alternative signaling pathways or acquired resistance, so it is often used clinically with the MEK inhibitor trametinib (Trametinib) are used in combination to enhance the tumor suppressor effect and delay drug resistance. In the future, research on the mechanism of dabrafenib may also be expanded to other BRAF mutation-related tumors, bringing therapeutic benefits to more patients.

Reference materials:https://www.drugs.com/